Home/Hedge Fund Intelligence/Tarsus Pharmaceuticals, Inc.
Nasdaq: TARSStockForm 13F30 Jun 2026

Hedge funds that hold Tarsus Pharmaceuticals, Inc. Nasdaq: TARS

CUSIP 87650L103 · who reports it, how much, and how much it matters to them

34 of the 720 hedge fund managers we track reported shares of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) on Form 13F for 30 June 2026. Between them they reported USD 696m. The largest position belongs to Deep Track Capital, at USD 231m.

Managers reporting it34of 720 we track
Value they reportUSD 696mshares only, 30 Jun 2026
Funds they run396with a file on PPLI.com
Largest positionUSD 231mDeep Track Capital
Typical weight0.0%median share of a manager's book
Heaviest weight3.4%Deep Track Capital

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

34 managers, USD 696m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Tarsus Pharmaceuticals, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Deep Track Capital1 fund on PPLI.comUSD 231m3.4%
2RTW Investments2 funds on PPLI.comUSD 211m1.8%
3Millennium Management6 funds on PPLI.comUSD 90m0.0%
4D. E. Shaw & Co.15 funds on PPLI.comUSD 45m0.0%
5Squarepoint Ops7 funds on PPLI.comUSD 19m0.0%
6Artisan Partners1 fund on PPLI.comUSD 18m0.0%
7Rock Springs Capital Management2 funds on PPLI.comUSD 17m0.9%
8Citadel Advisors32 funds on PPLI.comUSD 15m0.0%
9Cormorant Asset Management1 fund on PPLI.comUSD 6.3m0.3%
10Schonfeld Strategic Advisors30 funds on PPLI.comUSD 6.3m0.0%
11HighVista Strategies27 funds on PPLI.comUSD 5.5m1.2%
12Freestone Grove Partners1 fund on PPLI.comUSD 4.3m0.0%
13Eversept Partners3 funds on PPLI.comUSD 3.5m0.2%
14Cinctive Capital Management5 funds on PPLI.comUSD 2.9m0.1%
15Voleon Capital Management13 funds on PPLI.comUSD 2.7m0.1%
16PFM Health Sciences3 funds on PPLI.comUSD 2.6m0.2%
17Atika Capital Management3 funds on PPLI.comUSD 2.5m0.2%
18Two Sigma Investments35 funds on PPLI.comUSD 2.3m0.0%
19Orbimed Advisors1 fund on PPLI.comUSD 2.2m0.0%
20J. Goldman & Co.1 fund on PPLI.comUSD 1.7m0.0%
21Exoduspoint Capital Management7 funds on PPLI.comUSD 1.3m0.0%
22Jain Global1 fund on PPLI.comUSD 958,0000.0%
23Verition Fund Management3 funds on PPLI.comUSD 944,0000.0%
24Walleye Capital8 funds on PPLI.comUSD 749,0000.0%
25Tudor Investment Corporation10 funds on PPLI.comUSD 601,0000.0%
26Renaissance Technologies13 funds on PPLI.comUSD 585,0000.0%
27Brevan Howard Capital Management39 funds on PPLI.comUSD 503,0000.0%
28Capstone Investment Advisors25 funds on PPLI.comUSD 468,0000.0%
29Magnetar Financial93 funds on PPLI.comUSD 448,0000.0%
30Engineers Gate Manager1 fund on PPLI.comUSD 299,0000.0%
31Boothbay Fund Management2 funds on PPLI.comUSD 272,0000.0%
32Bayforest Capital1 fund on PPLI.comUSD 103,0000.1%
33Aquatic Capital Management3 funds on PPLI.comUSD 99,4450.0%
34The Quarry1 fund on PPLI.comUSD 2520.0%
Next: where it matters most
Where it matters most

For Deep Track Capital it is 3.4% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Deep Track CapitalUSD 231m3.4%
2RTW InvestmentsUSD 211m1.8%
3HighVista StrategiesUSD 5.5m1.2%
4Rock Springs Capital ManagementUSD 17m0.9%
5Cormorant Asset ManagementUSD 6.3m0.3%
6PFM Health SciencesUSD 2.6m0.2%
7Eversept PartnersUSD 3.5m0.2%
8Atika Capital ManagementUSD 2.5m0.2%
9Cinctive Capital ManagementUSD 2.9m0.1%
10Bayforest CapitalUSD 103,0000.1%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Tarsus Pharmaceuticals, Inc.

What is the ticker symbol of Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. trades under the symbol TARS on the Nasdaq. Its CUSIP, the code used on Form 13F, is 87650L103.

Which hedge funds own Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS)?

34 of the 720 hedge fund managers PPLI.com tracks reported Tarsus Pharmaceuticals, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Deep Track Capital (USD 231m), RTW Investments (USD 211m), Millennium Management (USD 90m), D. E. Shaw & Co. (USD 45m) and Squarepoint Ops (USD 19m).

How many hedge funds hold Tarsus Pharmaceuticals, Inc.?

34 managers in our coverage reported it, and between them they run 396 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Tarsus Pharmaceuticals, Inc.?

Deep Track Capital, where the position was 3.4% of the reported 13F book at 30 June 2026.

Does this show who is short Tarsus Pharmaceuticals, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Tarsus Pharmaceuticals, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.